SuppreMol appoints industry expert Michael Tansey as Chief Development Officer
(Thomson Reuters ONE) -
SuppreMol GmbH /
SuppreMol appoints industry expert Michael Tansey as Chief Development Officer
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Munich, Germany, September 10(th), 2013: SuppreMol GmbH, a privately held
biopharmaceutical company developing novel therapies for the treatment of
autoimmune diseases, today announced the appointment of Dr Michael Tansey as
Chief Development Officer (CDO) of the Company. At SuppreMol, Dr Tansey will
oversee both the non-clinical and clinical development of the Fc-gamma receptor
(FcgR) product family, in particular SM101, which is in Phase II clinical
development for Primary Immune Thrombocytopenia (ITP) and Systemic Lupus
Erythematosus (SLE).
Dr Tansey, who qualified in medicine in 1973, has more than 30 years of
successful international clinical development and management experience in the
pharmaceutical and biotech industry in Europe, the USA and Asia. He started his
career with Hoechst, followed by increasingly responsible roles in Glaxo and
Rhone-Poulenc Rohrer, expanding his career in large pharma as Chief Medical
Officer and Head of Medical Development at Pharmacia. Since 2003 he has
contributed his know-how and experience to several biotechnology companies,
including being CMO at NovaCardia and La Jolla Pharmaceutical Company prior to
joining SuppreMol. During his career Michael Tansey was involved in the
successful clinical development and regulatory approval of more than 15 small
molecule and biological products.
Dr Klaus Schollmeier, CEO of SuppreMol GmbH, said: "We are very pleased that Dr
Tansey is joining our Company at a time when SuppreMol is entering a new and
exciting phase. The Company has a very promising product candidate for the
treatment of autoimmune diseases in Phase II clinical development with important
clinical and regulatory milestones ahead. Dr Tansey brings the necessary
experience and knowledge for the Company to successfully advance SuppreMol's
clinical programs."
"SuppreMol's product candidates are based on innovative science and have shown
promising data in early clinical trials for the treatment of diseases for which
there is a medical need," stated Dr Michael Tansey, Chief Development Officer at
SuppreMol GmbH. "I look forward to spearheading the development of SM101, our
lead compound, with the intent of advancing this core asset successfully to the
key clinical and regulatory milestones."
About SuppreMol
SuppreMol GmbH is a privately held biopharmaceutical company developing novel
therapeutics for the treatment of autoimmune and allergic diseases. The company
is pioneering the development of soluble Fc-gamma receptors (FcgRs), which are
recombinant autologous therapeutic proteins with a specific immunoregulatory
potential. The company's lead product SM101, a recombinant soluble FcgRIIB is in
Phase II clinical development for the treatment of Primary Immune
Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) and has potential
to treat Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol's
pipeline also includes two antibody development programs utilizing the
inhibitory effect of FcgRIIB suitable for alternative treatment strategies and
indications. SuppreMol was founded as a spin-off from the laboratory of
Professor Dr Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max
Planck Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has
raised about ? 51 million through private investors. Major shareholders in the
company include MIG Fonds, BioMedPartners AG, Santo Holding GmbH and FCP Biotech
Holding GmbH along with KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck
Society, and Z-Cube.
Contact
SuppreMol GmbH
Dr Klaus Schollmeier
Chief Executive Officer
Tel: +49 89 30 90 50 680
E-mail: info(at)suppremol.com
www.suppremol.com
Press Release PDF:
http://hugin.info/155552/R/1728159/577075.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SuppreMol GmbH via Thomson Reuters ONE
[HUG#1728159]
Unternehmensinformation / Kurzprofil:
Datum: 10.09.2013 - 10:00 Uhr
Sprache: Deutsch
News-ID 294941
Anzahl Zeichen: 5012
contact information:
Town:
Martinsried/Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 148 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SuppreMol appoints industry expert Michael Tansey as Chief Development Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
SuppreMol GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
